Abstract
Trazodone's unique chemical structure reflects its distinct pharmacologic profile. Its antidepressant efficacy is postulated to occur through serotonin reuptake inhibition. It has little effect on other neurotransmitter systems. In the United States it has been studied in several double-blind trials which compared it to standard antidepressants and placebo. Both in- and outpatients spanning a spectrum of age and diagnoses have been studied. Trazodone has been shown to be at least as effective as standard antidepressants. There are few anticholinergic or cardiovascular side effects. Adverse reactions include drowsiness, dizziness, headache, nausea and rarely, priapism. It is relatively safe in overdose. Trazodone deserves special consideration in the treatment of patients with depression accompanied by marked agitation, anxiety, and insomnia, as well as those unable to tolerate anticholinergic side effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ali CJ, Henry JA (1980) Trazodone overdosage: experience over 5 years. Neuropsychobiology [Suppl 1] 15:44–45
Fabre LF, Feighner JP (1983) Long-term therapy for depression with trazodone. J Clin Psychiatry 44:17–21
Fabre LF, McLendon DM, Gainey A (1979), Trazodone efficacy in depression: a double-blind comparison with imipramine and placebo in day-hospital type patients. Curr Ther Res 25:827–834
Feighner JP (1980) Trazodone, a triazolopyridine derivative, in primary depressive disorder. J Clin Psychiatry 41:250–255
Feighner JP, Meredith CH, Hendrickson G (1981) Maintenance antidepressant therapy: a double-blind comparison of trazodone and imipramine. J Clin Psychopharmacol [Suppl 6] 1:45S–48S
Gamble DE, Peterson LG (1986) Trazodone overdose: four years of experience from voluntary reports. J Clin Psychiatry 47:544–546
Gerner R, Estabrook W, Steuer J, Jarvik L (1980) Treatment of geriatric depression with trazodone, imipramine, and placebo — a double-blind study. J Clin Psychiatry 41:216–220
Gershon S, Newton R (1980) Lack of anticholinergic side effects with a new antidepressant-trazodone. J Clin Psychiatry 41:100–104
Gershon S, Mann J, Newton R, Gunther BJ (1981) Evaluation of trazodone in the treatment of endogenous depression: results of a multicenter, double-blind study. J Clin Psychopharmacol [Suppl 6] 1:39S–44S
Goldberg HL, Finnerty RJ (1980) Trazodone in the treatment of neurotic depression. J Clin Psychiatry 41:430–434
Goldberg HL, Rickels K, Finnerty R (1981) Treatment of depression with a new antidepressant. J Clin Psychopharmacol [Suppl 6] 1:35S–38S
Hayes RL, Gerner RH, Fairbanks L, Moran M, Waltuch L (1983) ECG findings in geriatric patients given trazodone, placebo or imipramine. J Clin Psychiatry 44:180–183
Himmelhoch JM, Schechtman K, Auchenbach R (1984) The role of trazodone in the treatment of depressed cardiac patients. Psychopathology (1986) [Suppl 2] 17:51–63
Himmelhoch J (1986) Comparative study of trazodone and doxepin in the treatment of major depressive disorder. Curr Ther Res Clin Exp 39:1017–1026
Janowsky D, Curtis G, Zisook S, Kuhn K, Resovsky K, LeWinter M (1983) Ventricular arrhythmias possibly aggravated by trazodone. Am J Psychiatry 140:796–797
Kellams JJ, Klapper MH, Small JG (1979) Trazodone, a new antidepressant: efficacy and safety in endogenous depression. J Clin Psychiatry 40:390–395
Robinson DS, Corcella J, Feighner JP, Pohl R, Kelwala S, Mann JJ, Chien C, Gerner RH (1984) Comparison of trazodone, amoxapine and maprotiline in the treatment of endogenous depression: results of a multicenter study. Curr Ther Res Clin Exp 35:549–560
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feighner, J.P., Boyer, W.F. Overview of USA controlled trials of trazodone in clinical depression. Psychopharmacology 95, S50–S53 (1988). https://doi.org/10.1007/BF00172631
Issue Date:
DOI: https://doi.org/10.1007/BF00172631